Author(s): Wolchok J, Hoos A, O’Day S, Weber JS, Hamid O, et al.
Purpose: Immunotherapeutic agents produce antitumor effects by inducing cancer-specific immune responses or by modifying native immune processes. Resulting clinical response patterns extend beyond those of cytotoxic agents and can manifest after an initial increase in tumor burden or the appearance of new lesions (progressive disease). Response Evaluation Criteria in Solid Tumors or WHO criteria, designed to detect early effects of cytotoxic agents, may not provide a complete assessment of immunotherapeutic agents. Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required.
Referred From: https://aacrjournals.org/clincancerres/article/15/23/7412/74621/Guidelines-for-the-Evaluation-of-Immune-Therapy
Author(s): Chen D, Irving B, Hodi F
Author(s): Brahmer J, Tykodi S, Chow L, Hwu WJ, Topalian SL, et al.
Author(s): Brahmer J, Reckamp KL, Baas P, Crinò L, Wilfried EE, et al.
Author(s): Sundar R, Soong R, Cho B, Brahmer J, Soo R
Author(s): Solomon B, Varella-Garcia M, Camidge D
Author(s): Chin LP, Soo RA, Soong R, Ou S
Author(s): Grande C, Villanueva M, Huidobro G, Casal J
Author(s): Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, et al.
Author(s): Oxnard G, Morris M, Hodi F, Baker LH, Kris MG, et al.
